BioNTech Results Presentation Deck
Booster Dose of BNT162b2 Restores High Levels of Vaccine Effectiveness and
Prevents Against Severe Disease Across Diverse Population Groups, Globally
Real world vaccine effectiveness post primary dose schedule
Global data reflecting high vaccine effectiveness post primary regimen.
Population analysis from the Israeli Ministry of Health data found BNT162b2 had a
high level of VE across a range of outcomes ¹:
●
●
Asymptomatic disease:
Symptomatic disease:
COVID-19 hospitalizations:
Severe or critical hospitalization:
Death:
Vaccine effectiveness wanes with time post second dose
regardless of variant of concern but vaccine efficacy preventing
hospitalizations is maintained
Analysis of more than three
million US healthcare records²
demonstrated that BNT 162b2
was 90% (95% CI 89-92)
effective against
hospitalization
16
91.5% (95% CI: 90.7-92.2)
97.0% (95% CI: 96.7-97.2)
97.2% (95% CI: 96.8-97.5)
97.5% (95% CI: 97.1-97.8)
96.7% (95% CI: 96.0-97.3)
Adjusted estimated vaccine effectiveness (%)
100
90-
80-
70-
60-
50-
40
30-
20-
10
0
Variant
Delta
Other variant
Failed sequencing
<1
1 to <2
3 to <4
2 to <3
Time since full vaccination (months)
z4
Real world evidence that a booster dose restores high levels of
vaccine effectiveness for confirmed infections and severe
disease ³
●
Fold reduction in rate of
confirmed infections
●
Risk Reduction at ≥12 days after 3rd Dose Booster Compared
to Nonbooster by Age Group
25
20
15
10
5
0
16-29
30-39
40-49
Age Group
At ≥12 days post booster dose vs non-booster cohort:
10-fold risk reduction of confirmed infection (8.8-17.6) across all age groups
• 18.7-fold risk reduction in severe illness for ages 60+
¹Haas E, et al. Lancet 2021; https://doi.org/10.1016/S0140-6736(21)00947-8 Tartof S et al. Lancet 2021 https://doi.org/10.1016/S0140-6736(21)02183-8;
³Bar-On et al 2021 MedRxiv [preprint] DOI: https://doi.org/10.1101/2021.10.07.21264626
50-59
60+
22.0-fold risk reduction for severe illness for ages 40-60
14.7-fold risk reduction in COVID-19 associated deaths for ages 60+
BIONTECHView entire presentation